Get the Stockscreener App
0.4789
4.20%
-0.021
After Hours:
.49
0.0111
+2.32%
Ainos Inc stock is traded at $0.4789, with a volume of 205.19K.
It is down -4.20% in the last 24 hours and down -25.17% over the past month.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
See More
Previous Close:
$0.4999
Open:
$0.47
24h Volume:
205.19K
Relative Volume:
0.31
Market Cap:
$3.85M
Revenue:
$122.10K
Net Income/Loss:
$-13.77M
P/E Ratio:
-0.6301
EPS:
-0.76
Net Cash Flow:
$-4.79M
1W Performance:
+1.89%
1M Performance:
-25.17%
6M Performance:
-57.99%
1Y Performance:
-22.76%
1-Day Range:
$0.47
$0.5049
1-Week Range:
$0.4555
$0.599
52-Week Range:
$0.451
$4.2899
Ainos Inc Stock (AIMD) Company Profile
Name
Ainos Inc
Sector
Industry
Phone
858-869-2986
Address
AINOS, INC., SAN DIEGO
Ainos Inc Stock (AIMD) Latest News
AIMDWAinos, Inc. Warrants Latest Stock News & Market Updates - StockTitan
Ainos Inc (AIMD) Stock: A Year of Highs and Lows - The InvestChronicle
Ainos receives IRB nod for HIV-related oral wart trial - Investing.com
Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA - StockTitan
Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren’s Syndrome - StockTitan
Esperion Therapeutics (NASDAQ:ESPR) versus Ainos (NASDAQ:AIMD) Critical Analysis - Defense World
Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts - StockTitan
AIMD stock touches 52-week low at $0.45 amid market challenges - Investing.com
Ainos set for clinical trial of HIV treatment at Taiwan hospital - Investing.com
AIMDAinos, Inc. Latest Stock News & Market Updates - StockTitan
Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA - StockTitan
Financial Review: Ainos (OTCMKTS:AIMD) versus Siemens Healthineers (OTCMKTS:SMMNY) - Defense World
Ainos Leverages AI Nose for Safer, Smarter Factories - MSN
Ainos (NASDAQ:AIMD) Shares Down 6.6% - Defense World
Ainos secures Taiwan patent for antiviral drug VELDONA - Investing.com
Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention - Lelezard
Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention - StockTitan
Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Ainos (OTCMKTS:AIMD) Stock Price Up 6.1% - Defense World
Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter - PharmiWeb.com
Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter - AccessWire
Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter - StockTitan
Ainos Inc (AIMD) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Ainos Leverages AI Nose for Safer, Smarter Factories - AZoRobotics
Is the Ainos Inc (NASDAQ:AIMD) stock an investment opportunity? - US Post News
Ainos AI Nose achieves 79% accuracy in VOC detection - Investing.com India
Ainos AI Nose achieves 79% accuracy in VOC detection - Investing.com
Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety - AccessWire
Ainos Unveils AI Nose Breakthrough that Revolutionizes - GlobeNewswire
Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety - StockTitan
Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety - Big News Network
Ainos reports 79% identification accuracy of AI Nose - TipRanks
Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety - AsiaOne
Ainos, Inc. (NASDAQ:AIMD) Short Interest Update - Defense World
CXApp Inc [CXAI] moved down -25.76: Why It’s Important - The DBT News
Check out these key findings about Ainos Inc (AIMD) - SETE News
AIMD’s Stock Market Adventure: -70.20% YTD Growth Amidst Volatility - The InvestChronicle
AIMD’s price-to-book ratio: An indicator of the company’s performance - US Post News
Quarterly Metrics: Quick and Current Ratios for Ainos Inc (AIMD) - The Dwinnex
Why Is Ainos (AIMD) Stock Up 38% Today? - InvestorPlace
Ainos to Participate in Fireside Chat with Water Tower Research on August 22, 2024 - WICZ
Ainos to Participate in Fireside Chat with Water Tower Research on August 22, 2024 - StockTitan
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket - Benzinga
Ainos acquires licences for ten patents to improve point-of-care testing - Yahoo Finance
Ainos acquires licences for ten patents to improve point-of-care testing - Medical Device Network
Guangdong Baolihua New Energy Stock Co., Ltd. (000690.SZ) Latest Stock News & Headlines - Yahoo Finance
Ainos secures exclusive rights to 10 patents in healthcare tech - Investing.com India
Ainos secures exclusive rights to 10 patents in healthcare tech - Investing.com
Ainos Secures Tech Boost, Expands Portfolio and Settles Debt - TipRanks
Ainos secures exclusive rights to 10 patents in healthcare tech By Investing.com - Investing.com UK
Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing - StockTitan
Ainos Inc Stock (AIMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):